Leap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher

Leap Therapeutics, Inc. (NASDAQ:LPTX) shares traded up 0.6% on Friday . The company traded as high as $3.28 and last traded at $3.19. 334,593 shares changed hands during trading, an increase of 8% from the average session volume of 308,469 shares. The stock had previously closed at $3.17.

Analysts Set New Price Targets

A number of research analysts have recently commented on LPTX shares. Robert W. Baird decreased their price objective on shares of Leap Therapeutics from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, March 19th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Leap Therapeutics in a report on Tuesday, March 19th.

Leap Therapeutics Stock Up 0.6 %

The company’s fifty day moving average price is $2.77 and its 200 day moving average price is $2.76. The company has a market capitalization of $81.66 million, a P/E ratio of -0.63 and a beta of 0.54.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.10. Research analysts predict that Leap Therapeutics, Inc. will post -2.08 earnings per share for the current fiscal year.

Institutional Trading of Leap Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC grew its stake in shares of Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company’s stock worth $676,000 after buying an additional 185,001 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Leap Therapeutics during the third quarter worth $489,000. Key Client Fiduciary Advisors LLC grew its stake in shares of Leap Therapeutics by 8.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 233,018 shares of the company’s stock worth $620,000 after buying an additional 18,408 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Leap Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 46,994 shares of the company’s stock worth $65,000 after buying an additional 23,497 shares during the last quarter. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.